Search Within

Ryan Brett Sugarman

Formats
  1. Meeting Abstract (8)
  2. Journal Article (7)
Groups
  1. Department of Medicine (15)
  2. Gastrointestinal Oncology Service (15)
  3. Solid Tumor Oncology Division (15)
  4. Department of Pathology and Laboratory Medicine (9)
  5. Survivorship Research (9)
  6. Center for Pancreatic Cancer Research (8)

More Groups

People
  1. Laura Tang (7)
  2. Avni Desai (6)
  3. David Ilson (6)
  4. Geoffrey Ku (6)
  5. Marina Shcherba (6)
  6. Steven Maron (6)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (5)
  4. 2022 (6)
  5. 2021 (1)
  6. 2020 (1)
Publications
  1. Journal of Clinical Oncology (7)
  2. Nature (2)
  3. Annals of Oncology (1)
  4. Annals of Surgery (1)
  5. Clinical Therapeutics (1)
  6. Gastric Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (7)
  2. Nature Publishing Group (2)
  3. Elsevier Inc. (1)
  4. Elsevier Science, Inc. (1)
  5. Lippincott Williams & Wilkins (1)
  6. Massachusetts Medical Society (1)

More Publishers

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer
    Journal Article

    Sethna, Z.; Guasp, P.; Reiche, C.; Milighetti, M.; Ceglia, N.; Patterson, E.; Lihm, J.; Payne, G.; Lyudovyk, O.; Rojas, L. A.; more...
    Nature (2025)

    Fulltext@MSK | Save
  • Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649)
    Meeting Abstract

    Lin, D.; Quan, W.; Garretson, M.; Chirikov, V.; Chen, C.; Singh, P.; Davis, C.; Sugarman, R.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: Analysis of number needed to treat and number needed to harm
    Journal Article

    Sugarman, R.; Betts, K. A.; Nie, X.; Hartman, J.; Nguyen, H.
    Clinical Therapeutics (2023)

    Fulltext@MSK | Save
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Durvalumab and PET-directed chemoradiation in locally advanced esophageal adenocarcinoma: A phase Ib/II study
    Journal Article

    Cowzer, D.; Wu, A. J. C.; Sihag, S.; Walch, H. S.; Park, B. J.; Jones, D. R.; Gu, P.; Maron, S. B.; Sugarman, R.; Chalasani, S. B.; more...
    Annals of Surgery (2023)

    Fulltext@MSK | Save
  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
    Journal Article

    Rojas, L. A.; Sethna, Z.; Soares, K. C.; Olcese, C.; Pang, N.; Patterson, E.; Lihm, J.; Ceglia, N.; Guasp, P.; Chu, A.; more...
    Nature (2023)

    Fulltext@MSK | Save
  • Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
    Journal Article

    Lin, D.; Nguyen, H.; Shah, R.; Qiao, Y.; Hartman, J.; Sugarman, R.
    Gastric Cancer (2023)

    Fulltext@MSK | Save
  • Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
    Meeting Abstract

    Cytryn, S.; Joshi, S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; Rao, D.; Goldberg, Z.; Sugarman, R.; Antoine, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results
    Meeting Abstract

    Cowzer, D.; Wu, A. J. C.; Sihag, S.; Walch, H. S.; Park, B. J.; Jones, D. R.; Gu, P.; Maron, S. B.; Sugarman, R.; Chalasani, S. B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer
    Journal Article

    Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; Lamendola-Essel, M.; El Dika, I. H.; Segal, N.; Shcherba, M.; Sugarman, R.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save